vegf  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Name:
    Vascular Endothelial Growth Factor VEGF
    Description:

    Catalog Number:
    rm-9128-pcs
    Price:
    None
    Buy from Supplier


    Structured Review

    Thermo Fisher vegf
    Multi-level correlation network that includes all participants in the study. For further explanations, see text. Abbreviations: Abs: absolute count; HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; TNF: Tumour necrosis factor; <t>TGF-ß:</t> Transforming growth factor beta; <t>VEGF:</t> Vascular endothelial growth factor; IGF: Insulin-like growth factor; IL: Interleukin; RBC: Red blood cells; WBC: White blood cells; Lympho: Lymphocytes; Segmented: segmented neutrophils; E. Polychrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E. Ortochrom: Ortochromatic erythroblast; T cells: T lymphocytes; B cells: B lymphocytes; Plasmatic: Plasmatic cells; Hb: haemoglobin; Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages; MFI: Mean fluorescence intensity; Mono: Monocyte; Neutro: Neutrophil; Bas: Basophil; Mφ: Macrophage; FEV1: forced expiratory volume in 1st second; DLCO: Diffusing capacity of the lung for carbon monoxide; BMI: body mass index

    https://www.bioz.com/result/vegf/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2021-03
    99/100 stars

    Images

    1) Product Images from "Bone marrow characterization in COPD: a multi-level network analysis"

    Article Title: Bone marrow characterization in COPD: a multi-level network analysis

    Journal: Respiratory Research

    doi: 10.1186/s12931-018-0824-x

    Multi-level correlation network that includes all participants in the study. For further explanations, see text. Abbreviations: Abs: absolute count; HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; TNF: Tumour necrosis factor; TGF-ß: Transforming growth factor beta; VEGF: Vascular endothelial growth factor; IGF: Insulin-like growth factor; IL: Interleukin; RBC: Red blood cells; WBC: White blood cells; Lympho: Lymphocytes; Segmented: segmented neutrophils; E. Polychrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E. Ortochrom: Ortochromatic erythroblast; T cells: T lymphocytes; B cells: B lymphocytes; Plasmatic: Plasmatic cells; Hb: haemoglobin; Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages; MFI: Mean fluorescence intensity; Mono: Monocyte; Neutro: Neutrophil; Bas: Basophil; Mφ: Macrophage; FEV1: forced expiratory volume in 1st second; DLCO: Diffusing capacity of the lung for carbon monoxide; BMI: body mass index
    Figure Legend Snippet: Multi-level correlation network that includes all participants in the study. For further explanations, see text. Abbreviations: Abs: absolute count; HSC: Hematopoietic stem cells; EPC: Endothelial progenitor cells; TNF: Tumour necrosis factor; TGF-ß: Transforming growth factor beta; VEGF: Vascular endothelial growth factor; IGF: Insulin-like growth factor; IL: Interleukin; RBC: Red blood cells; WBC: White blood cells; Lympho: Lymphocytes; Segmented: segmented neutrophils; E. Polychrom: Polychromatic erythroblast; E. Basophils: Basophils erythroblast; E. Ortochrom: Ortochromatic erythroblast; T cells: T lymphocytes; B cells: B lymphocytes; Plasmatic: Plasmatic cells; Hb: haemoglobin; Eos: Eosinophils; Mono/Macro: Monocyte/Macrophages; MFI: Mean fluorescence intensity; Mono: Monocyte; Neutro: Neutrophil; Bas: Basophil; Mφ: Macrophage; FEV1: forced expiratory volume in 1st second; DLCO: Diffusing capacity of the lung for carbon monoxide; BMI: body mass index

    Techniques Used: Fluorescence

    2) Product Images from "Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study"

    Article Title: Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: in vitro and in vivo study

    Journal: American Journal of Cancer Research

    doi:

    Neddylation pathway is involved in VEGF-activated angiogenesis; MLN4924 diminished cell proliferation induced by VEGF in HUVECs via Neddylation Blockade. A. HUVECs were treated with VEGF (50 ng/mL) at various time points (2, 5, 30, 45 minutes) and various concentrations of VEGF (0, 25 and 50 ng/ml) for 24 h. Cell lysates were analyzed by western blot for UBC12. B. HUVECs were treated with VEGF (50 ng/mL) without or with MLN4924 (50-500 nM). Percentage of cell viability in HUVECs after 24-h treatment with MLN4924 is shown. Data are presented as mean ± SD. Asterisks and pounds indicate the degree of statistical difference; *P ≤ 0.05 as compared with VEGF-treated control. C. HUVECs were treated with VEGF (50 ng/mL) without or with MLN4924 (500 nM). Cell lysates were analyzed by western blot for UBC12, cleaved PARP, cleaved caspase-3 and cleaved caspase-7. D. HUVECs were treated with VEGF (50 ng/mL) with or without MLN4924 (50-1000 nM). Cell lysates were harvested and subjected to western blot using specific antibodies against phosphor-Erk1/2 and Erk1/2. Results are representative of at least three independent experiments.
    Figure Legend Snippet: Neddylation pathway is involved in VEGF-activated angiogenesis; MLN4924 diminished cell proliferation induced by VEGF in HUVECs via Neddylation Blockade. A. HUVECs were treated with VEGF (50 ng/mL) at various time points (2, 5, 30, 45 minutes) and various concentrations of VEGF (0, 25 and 50 ng/ml) for 24 h. Cell lysates were analyzed by western blot for UBC12. B. HUVECs were treated with VEGF (50 ng/mL) without or with MLN4924 (50-500 nM). Percentage of cell viability in HUVECs after 24-h treatment with MLN4924 is shown. Data are presented as mean ± SD. Asterisks and pounds indicate the degree of statistical difference; *P ≤ 0.05 as compared with VEGF-treated control. C. HUVECs were treated with VEGF (50 ng/mL) without or with MLN4924 (500 nM). Cell lysates were analyzed by western blot for UBC12, cleaved PARP, cleaved caspase-3 and cleaved caspase-7. D. HUVECs were treated with VEGF (50 ng/mL) with or without MLN4924 (50-1000 nM). Cell lysates were harvested and subjected to western blot using specific antibodies against phosphor-Erk1/2 and Erk1/2. Results are representative of at least three independent experiments.

    Techniques Used: Western Blot

    MLN4924 inhibits VEGF-activated cell migration, capillary tube formation, and the downstream angiogenetic pathway in HUVECs. A. Representative image of Transwell TM migration of HUVECs recorded via time-lapse microscope (100×). Data are presented as mean ± SD. Asteris ks indicate the degree of statistical difference: *P ≤ 0.05 as compared with VEGF-treated control. #P ≤ 0.05 as compared with non-treated control. B. HUVECs were seeded into a Matrigel TM -coated 48-well plate and treated with 100 or 500 nM MLN4924 for 24 h. Photographs of tube formation are shown (100×). C. In vivo Matrigel TM plug assay. Matrigel TM containing the indicated amount of DMSO, VEGF (125 ng), or VEGF plus MLN4924 (0.5 mM and 5 mM) was injected into 6-week-old FVB mice subcutaneously (n = 8/dose). After 5 days, Matrigel TM plugs were excised and photographed. The hemoglobin concentration in each plug was analyzed. Asterisks and pound symbols indicate the degree of statistical difference: *P ≤ 0.05 as compared to VEGF-treated group. #P
    Figure Legend Snippet: MLN4924 inhibits VEGF-activated cell migration, capillary tube formation, and the downstream angiogenetic pathway in HUVECs. A. Representative image of Transwell TM migration of HUVECs recorded via time-lapse microscope (100×). Data are presented as mean ± SD. Asteris ks indicate the degree of statistical difference: *P ≤ 0.05 as compared with VEGF-treated control. #P ≤ 0.05 as compared with non-treated control. B. HUVECs were seeded into a Matrigel TM -coated 48-well plate and treated with 100 or 500 nM MLN4924 for 24 h. Photographs of tube formation are shown (100×). C. In vivo Matrigel TM plug assay. Matrigel TM containing the indicated amount of DMSO, VEGF (125 ng), or VEGF plus MLN4924 (0.5 mM and 5 mM) was injected into 6-week-old FVB mice subcutaneously (n = 8/dose). After 5 days, Matrigel TM plugs were excised and photographed. The hemoglobin concentration in each plug was analyzed. Asterisks and pound symbols indicate the degree of statistical difference: *P ≤ 0.05 as compared to VEGF-treated group. #P

    Techniques Used: Migration, Microscopy, In Vivo, Plug Assay, Injection, Mouse Assay, Concentration Assay

    3) Product Images from "The Efficacy of Autologous Myoblast Sheet Transplantation to Prevent Perforation After Duodenal Endoscopic Submucosal Dissection in Porcine Model"

    Article Title: The Efficacy of Autologous Myoblast Sheet Transplantation to Prevent Perforation After Duodenal Endoscopic Submucosal Dissection in Porcine Model

    Journal: Cell Transplantation

    doi: 10.1177/0963689720963882

    Gene expression profile analysis of myoblast and fibroblast sheets. (A) qRT-PCR confirmed the expression of the specific gene of myoblast cell DES, MyoD, INTGα7, and PAX7. (B) mRNAs of growth factors TGFβ1, FGF2, and VEGF of myoblasts showed increased expression as compared to fibroblasts. The data are shown as mean ± SD. * P
    Figure Legend Snippet: Gene expression profile analysis of myoblast and fibroblast sheets. (A) qRT-PCR confirmed the expression of the specific gene of myoblast cell DES, MyoD, INTGα7, and PAX7. (B) mRNAs of growth factors TGFβ1, FGF2, and VEGF of myoblasts showed increased expression as compared to fibroblasts. The data are shown as mean ± SD. * P

    Techniques Used: Expressing, Quantitative RT-PCR

    4) Product Images from "Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102"

    Article Title: Sequential Loss of Tumor Vessel Pericytes and Endothelial Cells after Inhibition of Platelet-Derived Growth Factor B by Selective Aptamer AX102

    Journal: Cancer research

    doi: 10.1158/0008-5472.CAN-07-0293

    Specificity of AX102 and AX102-mediated reduction in tumor pericytes. A , in nitrocellulose filtration assays, AX102 bound with high affinities to PDGF-BB and PDGF-AB, but not to PDGF-AA, PDGF-CC, or VEGF 165 ( i ). Cross-reactivity to rodent PDGF was shown
    Figure Legend Snippet: Specificity of AX102 and AX102-mediated reduction in tumor pericytes. A , in nitrocellulose filtration assays, AX102 bound with high affinities to PDGF-BB and PDGF-AB, but not to PDGF-AA, PDGF-CC, or VEGF 165 ( i ). Cross-reactivity to rodent PDGF was shown

    Techniques Used: Filtration

    5) Product Images from "Efficient differentiation of human embryonic stem cells to arterial and venous endothelial cells under feeder- and serum-free conditions"

    Article Title: Efficient differentiation of human embryonic stem cells to arterial and venous endothelial cells under feeder- and serum-free conditions

    Journal: Stem Cell Research & Therapy

    doi: 10.1186/s13287-015-0260-5

    Schematic diagram summarizing the protocol for differentiation of hESCs to endothelial phenotypes. Schematic representation depicts the differentiation of hESCs to endothelial progenitors and further towards venous and arterial endothelial phenotypes that upon transplantation form functional microvessels in vivo. bFGF Basic fibroblast growth factor, BMP4 Bone morphogenetic protein 4, EC Endothelial cells, EGF Epidermal growth factor, hESC Human embryonic stem cells, VEGF Vascular endothelial growth factor
    Figure Legend Snippet: Schematic diagram summarizing the protocol for differentiation of hESCs to endothelial phenotypes. Schematic representation depicts the differentiation of hESCs to endothelial progenitors and further towards venous and arterial endothelial phenotypes that upon transplantation form functional microvessels in vivo. bFGF Basic fibroblast growth factor, BMP4 Bone morphogenetic protein 4, EC Endothelial cells, EGF Epidermal growth factor, hESC Human embryonic stem cells, VEGF Vascular endothelial growth factor

    Techniques Used: Transplantation Assay, Functional Assay, In Vivo

    Kinetics of transcripts associated with early endothelial induction and pluripotency of human embryonic stem cells ( hESCs ). a Schematic representation of differentiation of H1-hESCs towards endothelial progenitors by sequential treatment with CHIR99021 ( +GSKi ) and basic fibroblast growth factor ( bFGF ) for 24 hours each followed by exposure to bone morphogenetic protein 4 ( BMP4 ) and/or vascular endothelial growth factor ( VEGF ). b Kinetics of expression of VEGFR2 , CD34 and CD31 upon induction with BMP4 ( Gi.F.B ), VEGF ( Gi.F.V ) and BMP4 + VEGF ( Gi.F.BV ) over a differentiation period of 5 days. c Time course expression kinetics of pluripotency genes ( OCT4 , SOX2 , NANOG ) over 5 days of differentiation among the three differentiation conditions. For gene expression plots in ( b ) expression levels were normalized to corresponding β-ACTIN values and are shown relative to undifferentiated hESCs, while for those in ( c ) the expression levels were log-normalized to reveal the amount of downregulation in relation to undifferentiated hESCs. Error bars show standard deviations; n ≥ 3. * p
    Figure Legend Snippet: Kinetics of transcripts associated with early endothelial induction and pluripotency of human embryonic stem cells ( hESCs ). a Schematic representation of differentiation of H1-hESCs towards endothelial progenitors by sequential treatment with CHIR99021 ( +GSKi ) and basic fibroblast growth factor ( bFGF ) for 24 hours each followed by exposure to bone morphogenetic protein 4 ( BMP4 ) and/or vascular endothelial growth factor ( VEGF ). b Kinetics of expression of VEGFR2 , CD34 and CD31 upon induction with BMP4 ( Gi.F.B ), VEGF ( Gi.F.V ) and BMP4 + VEGF ( Gi.F.BV ) over a differentiation period of 5 days. c Time course expression kinetics of pluripotency genes ( OCT4 , SOX2 , NANOG ) over 5 days of differentiation among the three differentiation conditions. For gene expression plots in ( b ) expression levels were normalized to corresponding β-ACTIN values and are shown relative to undifferentiated hESCs, while for those in ( c ) the expression levels were log-normalized to reveal the amount of downregulation in relation to undifferentiated hESCs. Error bars show standard deviations; n ≥ 3. * p

    Techniques Used: Expressing

    Flow cytometry characterization of terminal differentiation of CD34 + CD31 + endothelial progenitors to venous and arterial endothelial cells under serum-free conditions. a Schematic representation of differentiation of hESCs to endothelial progenitors and further differentiation towards venous ECs ( hESC-Ven-ECs ) and arterial ECs ( hESC-Art-ECs ). b Representative flow cytometry histogram overlays represent the expression of pan-endothelial, arterial and venous markers among H1-Ven-ECs, H1-Art-ECs, H9-Ven-ECs, H9-Art-ECs, HUVECs, and HCAECs. bFGF Basic fibroblast growth factor, BMP4 Bone morphogenetic protein 4, EGF Epidermal growth factor, GSKi Glycogen synthase kinase inhibitor (CHIR99021), HCAEC Human coronary artery endothelial cells, hESC Human embryonic stem cells, HUVEC Human umbilical vein endothelial cells, VEGF Vascular endothelial growth factor
    Figure Legend Snippet: Flow cytometry characterization of terminal differentiation of CD34 + CD31 + endothelial progenitors to venous and arterial endothelial cells under serum-free conditions. a Schematic representation of differentiation of hESCs to endothelial progenitors and further differentiation towards venous ECs ( hESC-Ven-ECs ) and arterial ECs ( hESC-Art-ECs ). b Representative flow cytometry histogram overlays represent the expression of pan-endothelial, arterial and venous markers among H1-Ven-ECs, H1-Art-ECs, H9-Ven-ECs, H9-Art-ECs, HUVECs, and HCAECs. bFGF Basic fibroblast growth factor, BMP4 Bone morphogenetic protein 4, EGF Epidermal growth factor, GSKi Glycogen synthase kinase inhibitor (CHIR99021), HCAEC Human coronary artery endothelial cells, hESC Human embryonic stem cells, HUVEC Human umbilical vein endothelial cells, VEGF Vascular endothelial growth factor

    Techniques Used: Flow Cytometry, Cytometry, Expressing

    Flow cytometry analysis of induction of H1-hESCs towards endothelial lineage. Representative flow cytometry overlays display the kinetics of co-expression of vascular endothelial growth factor receptor-2 ( VEGFR2 ) and CD34 ( a ), and CD31 and CD34 ( b ) upon induction of H1-hESCs with BMP4 ( Gi.F.B ), VEGF ( Gi.F.V ) and BMP4 + VEGF ( Gi.F.BV ) over a differentiation period of 5 days
    Figure Legend Snippet: Flow cytometry analysis of induction of H1-hESCs towards endothelial lineage. Representative flow cytometry overlays display the kinetics of co-expression of vascular endothelial growth factor receptor-2 ( VEGFR2 ) and CD34 ( a ), and CD31 and CD34 ( b ) upon induction of H1-hESCs with BMP4 ( Gi.F.B ), VEGF ( Gi.F.V ) and BMP4 + VEGF ( Gi.F.BV ) over a differentiation period of 5 days

    Techniques Used: Flow Cytometry, Cytometry, Expressing

    6) Product Images from "A Modular Microscale Granuloma Model for Immune-Microenvironment Signaling Studies in vitro"

    Article Title: A Modular Microscale Granuloma Model for Immune-Microenvironment Signaling Studies in vitro

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2020.00931

    Soluble factor analysis of granuloma layer supernatants illustrates proinflammatory profile of infection model. Infection with BCG causes significant increases in secretion of (A) IL-6 and (C) VEGF in the Stacks platform, and shows an increasing trend in (B) TNFα secretion Day 1 p.i. Secretion of IL-6, TNFα, and VEGF decreases over time in infected granuloma layers following infection, corresponding with the formation of aggregates starting around Day 3 p.i. For Day 1–5 p.i., media was replaced daily and supernatant collected from each day was analyzed. Each point represents pooled supernatant samples from 24 technical replicates from n = 4 independent experiments. Error bars: SEM. * P
    Figure Legend Snippet: Soluble factor analysis of granuloma layer supernatants illustrates proinflammatory profile of infection model. Infection with BCG causes significant increases in secretion of (A) IL-6 and (C) VEGF in the Stacks platform, and shows an increasing trend in (B) TNFα secretion Day 1 p.i. Secretion of IL-6, TNFα, and VEGF decreases over time in infected granuloma layers following infection, corresponding with the formation of aggregates starting around Day 3 p.i. For Day 1–5 p.i., media was replaced daily and supernatant collected from each day was analyzed. Each point represents pooled supernatant samples from 24 technical replicates from n = 4 independent experiments. Error bars: SEM. * P

    Techniques Used: Infection

    7) Product Images from "Glial-Derived Growth Factor and Pleiotrophin Synergistically Promote Axonal Regeneration in Critical Nerve Injuries"

    Article Title: Glial-Derived Growth Factor and Pleiotrophin Synergistically Promote Axonal Regeneration in Critical Nerve Injuries

    Journal: Acta biomaterialia

    doi: 10.1016/j.actbio.2018.07.048

    Effect of PTN and VEGF in nerve regeneration across a 3 cm-long nerve gap. (A) Photographs of regenerated nerves 9 weeks after implantation. Collagen-filled conduits failed to mediate nerve growth. Conversely, BNIs with collagen, VEGF-MPs or PTN-MPs showed nerve regeneration. (B) Axonal growth in the BNI was confirmed by positive NFP staining. (C) Representative growth inside the microchannels at the middle of the conduit is shown at higher magnification. (D) Double labeling of axons (β-tubulin) and myelin (P0), confirmed nerve regeneration across the gap. (E) The number of axons per channel and (F) distal to the implant showed a mild effect of PTN. *** = p ≤ 0.001. Scale bars: A) 0.5 cm, (B) 350 μm, (C and D) 50 μm.
    Figure Legend Snippet: Effect of PTN and VEGF in nerve regeneration across a 3 cm-long nerve gap. (A) Photographs of regenerated nerves 9 weeks after implantation. Collagen-filled conduits failed to mediate nerve growth. Conversely, BNIs with collagen, VEGF-MPs or PTN-MPs showed nerve regeneration. (B) Axonal growth in the BNI was confirmed by positive NFP staining. (C) Representative growth inside the microchannels at the middle of the conduit is shown at higher magnification. (D) Double labeling of axons (β-tubulin) and myelin (P0), confirmed nerve regeneration across the gap. (E) The number of axons per channel and (F) distal to the implant showed a mild effect of PTN. *** = p ≤ 0.001. Scale bars: A) 0.5 cm, (B) 350 μm, (C and D) 50 μm.

    Techniques Used: Staining, Labeling

    8) Product Images from "Multiple CD11c+ cells collaboratively express IL-1β to modulate stromal vascular endothelial growth factor and lymph node vascular-stromal growth"

    Article Title: Multiple CD11c+ cells collaboratively express IL-1β to modulate stromal vascular endothelial growth factor and lymph node vascular-stromal growth

    Journal: Journal of immunology (Baltimore, Md. : 1950)

    doi: 10.4049/jimmunol.1301765

    IL-1β and VEGF are both at the outer T zones (A–C) Nearby sections from a day 2 draining popliteal lymph node were stained for indicated markers. (A) CD11b. B cell follicles “F”, the T zone “T”, and medulla “M” are marked. (B) IL-1β. (C) Control IgG for IL-1β stain. IL-1β −/− also showed no staining with IL-1β antibody (data not shown). (D–E) Nearby sections from a day 2 popliteal node stained for (D) IL-1b and laminin and (E) CD11b and laminin. (F–G) Day 2 draining popliteal node from VEGF-lacZ reporter mouse stained for (F) CD11b (G) β-galactosidase activity and laminin. (H) Enlargement of upper aspect of (G). All images are representative of lymph nodes from at least 2 mice. Scale bar =100um.
    Figure Legend Snippet: IL-1β and VEGF are both at the outer T zones (A–C) Nearby sections from a day 2 draining popliteal lymph node were stained for indicated markers. (A) CD11b. B cell follicles “F”, the T zone “T”, and medulla “M” are marked. (B) IL-1β. (C) Control IgG for IL-1β stain. IL-1β −/− also showed no staining with IL-1β antibody (data not shown). (D–E) Nearby sections from a day 2 popliteal node stained for (D) IL-1b and laminin and (E) CD11b and laminin. (F–G) Day 2 draining popliteal node from VEGF-lacZ reporter mouse stained for (F) CD11b (G) β-galactosidase activity and laminin. (H) Enlargement of upper aspect of (G). All images are representative of lymph nodes from at least 2 mice. Scale bar =100um.

    Techniques Used: Staining, Activity Assay, Mouse Assay

    CD11c+CD11b+ cells induce FRCs to upregulate VEGF in an IL-1β-dependent manner in vitro (A) Characterization of CD11b+ and CD11b− cells isolated from RAG1−/− lymph nodes at day 2 after immunization. (B) Characterization of cultured FRCs. Upper plot is of FRCs that were passage 1 at time of plating and examined 2 days after plating. Lower graph shows the increase in Thy1 hi cells with passage number. (C–D) Histograms showing (C) VEGF and (D) CCL21 expression in cultured FRCS (E) VEGF protein levels in supernatant of FRCs co-cultured with CD11b+ or CD11b− cells. N=10 wells over 4 experiments. (F) VEGF mRNA in FRCs after co-culture. N=3 samples over 3 experiments. (G) VEGF protein levels in supernatant of FRCs co-cultured with wild-type or IL-1β−/− CD11b+ cells. N=9 wells per condition over 3 experiments. (H) VEGF mRNA in FRCs after co-culture with wild-type or IL-1β−/− CD11b+ cells. The specific VEGF isoforms evaluated are as indicated. N=4 samples per condition over 4 experiments. For (E–H), *=p > .05 and **=p
    Figure Legend Snippet: CD11c+CD11b+ cells induce FRCs to upregulate VEGF in an IL-1β-dependent manner in vitro (A) Characterization of CD11b+ and CD11b− cells isolated from RAG1−/− lymph nodes at day 2 after immunization. (B) Characterization of cultured FRCs. Upper plot is of FRCs that were passage 1 at time of plating and examined 2 days after plating. Lower graph shows the increase in Thy1 hi cells with passage number. (C–D) Histograms showing (C) VEGF and (D) CCL21 expression in cultured FRCS (E) VEGF protein levels in supernatant of FRCs co-cultured with CD11b+ or CD11b− cells. N=10 wells over 4 experiments. (F) VEGF mRNA in FRCs after co-culture. N=3 samples over 3 experiments. (G) VEGF protein levels in supernatant of FRCs co-cultured with wild-type or IL-1β−/− CD11b+ cells. N=9 wells per condition over 3 experiments. (H) VEGF mRNA in FRCs after co-culture with wild-type or IL-1β−/− CD11b+ cells. The specific VEGF isoforms evaluated are as indicated. N=4 samples per condition over 4 experiments. For (E–H), *=p > .05 and **=p

    Techniques Used: In Vitro, Isolation, Cell Culture, Expressing, Co-Culture Assay

    9) Product Images from "Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease"

    Article Title: Role of the HIF-1 signaling pathway in chronic obstructive pulmonary disease

    Journal: Experimental and Therapeutic Medicine

    doi: 10.3892/etm.2018.6785

    Expression of (A) hypoxia inducible factor-1α, (B) VEGF and (C) VEGF receptor 2 was observed to be increased in the lung epithelium collected from smoking chronic obstructive pulmonary disease subjects, as detected by immunohistochemistry (magnification, ×200 and ×400 as indicated). VEGF, vascular endothelial growth factor.
    Figure Legend Snippet: Expression of (A) hypoxia inducible factor-1α, (B) VEGF and (C) VEGF receptor 2 was observed to be increased in the lung epithelium collected from smoking chronic obstructive pulmonary disease subjects, as detected by immunohistochemistry (magnification, ×200 and ×400 as indicated). VEGF, vascular endothelial growth factor.

    Techniques Used: Expressing, Immunohistochemistry

    10) Product Images from "Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice"

    Article Title: Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI58128

    Pro-tumorigenic activity of endothelium-derived EETs is mediated by VEGF induction and loss of TSP1.
    Figure Legend Snippet: Pro-tumorigenic activity of endothelium-derived EETs is mediated by VEGF induction and loss of TSP1.

    Techniques Used: Activity Assay, Derivative Assay

    Related Articles

    Mutagenesis:

    Article Title: Apelin Affects the Progression of Osteoarthritis by Regulating VEGF-Dependent Angiogenesis and miR-150-5p Expression in Human Synovial Fibroblasts
    Article Snippet: .. The mutant 3′UTR region of VEGF mRNA (mt-IL-VEGF-3′-UTR) was purchased from Invitrogen. .. The Dual-Luciferase® Reporter Assay System was bought from Promega (Madison, WI, USA).

    Staining:

    Article Title: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo
    Article Snippet: Determination of VEGF-A, VEGF-C, VEGF-D, VEGFR-2, VEGFR-3 in vitro and in vivo The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 at protein and mRNA levels from the 3-D culture of HDLECs or the co-culture system in vitro , and the in-situ xenografts in vivo were determined by S-P staining, western blotting and fluorescent quantitative RT-PCR as described previously [ , ]. .. For S-P staining, slides were treated according to the kit brochure (Jinmei Biotechnology Co., Ltd., Shanghai), added in order with primary antibody [rabbit anti-human monoclonal antibody VEGF-A (Santa Gruz), VEGF-C (Invitrogen), VEGF-D (Abcam, USA), VEGFR-2 (Cell Signaling, USA), VEGFR-3 (Cell Signaling), biotinylated anti-rabbit secondary, HRP logo Streptavidin and DAB solution, respectively. .. Then, slides were rinsed, dehydrated, mounted and observed under an optic microscope (Olympus, Japan).

    Article Title: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF
    Article Snippet: Histological preparations were examined using an Olympus BX60 microscope (Olympus, Melville, NY, USA), at magnifications of × 100 and × 400, and a photographic record was obtained using a Zeiss Axiocam camera. .. Immunohistochemical staining with various antibodies including GLUT1 (1:400, Alpha Diagnostic International, San Antonio, TX, USA), VEGF (1:200, Lab Vision, CA, USA), tenascin, phospho-PKCα (p-PKCα), and PKCβ1 (all 1:100, Santa Cruz Biotechnology, CA, USA), fibronectin (FN) and laminin (both 1:100, Sigma-Aldrich, St Louis, MO, USA), collagen IV (1:100, Santa Cruz Biotechnology, against α-1, α-3, and α-5 chains), CD2AP (1:100, Abcam, Cambridge, MA, USA), nephrin and podocin (both 1:100, kind gifts from Dr L Holzman, University of Michigan) was conducted using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with some modifications. .. Briefly, 5 µm sections were deparaffinized, and endogenous peroxidase activity was ablated by incubation in 3% hydrogen peroxide in TBS (pH 7.4).

    Immunohistochemistry:

    Article Title: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF
    Article Snippet: Histological preparations were examined using an Olympus BX60 microscope (Olympus, Melville, NY, USA), at magnifications of × 100 and × 400, and a photographic record was obtained using a Zeiss Axiocam camera. .. Immunohistochemical staining with various antibodies including GLUT1 (1:400, Alpha Diagnostic International, San Antonio, TX, USA), VEGF (1:200, Lab Vision, CA, USA), tenascin, phospho-PKCα (p-PKCα), and PKCβ1 (all 1:100, Santa Cruz Biotechnology, CA, USA), fibronectin (FN) and laminin (both 1:100, Sigma-Aldrich, St Louis, MO, USA), collagen IV (1:100, Santa Cruz Biotechnology, against α-1, α-3, and α-5 chains), CD2AP (1:100, Abcam, Cambridge, MA, USA), nephrin and podocin (both 1:100, kind gifts from Dr L Holzman, University of Michigan) was conducted using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with some modifications. .. Briefly, 5 µm sections were deparaffinized, and endogenous peroxidase activity was ablated by incubation in 3% hydrogen peroxide in TBS (pH 7.4).

    Isolation:

    Article Title: Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio
    Article Snippet: Cell lines, media, fetal bovine serum (FBS), penicillin plus streptomycin solution, and trypsin-EDTA were obtained from American Tissue Culture Collection (ATCC, Rockville, MD, USA). .. Exosome isolation solution, RNeasy Mini Kit, vascular endothelial growth factor (VEGF) forward and reverse primers, iTaq™ Universal SYBR® Green One-Step Kit, and biological agents were purchased from Life Technologies (Grand Island, NY, USA). .. CD9, CD63, and CD81 antibodies, ELISA kits, and exosome-depleted FBS were obtained from System Biosciences Inc. (Mountain View, CA, USA).

    SYBR Green Assay:

    Article Title: Exosome Delivered Anticancer Drugs Across the Blood-Brain Barrier for Brain Cancer Therapy in Danio Rerio
    Article Snippet: Cell lines, media, fetal bovine serum (FBS), penicillin plus streptomycin solution, and trypsin-EDTA were obtained from American Tissue Culture Collection (ATCC, Rockville, MD, USA). .. Exosome isolation solution, RNeasy Mini Kit, vascular endothelial growth factor (VEGF) forward and reverse primers, iTaq™ Universal SYBR® Green One-Step Kit, and biological agents were purchased from Life Technologies (Grand Island, NY, USA). .. CD9, CD63, and CD81 antibodies, ELISA kits, and exosome-depleted FBS were obtained from System Biosciences Inc. (Mountain View, CA, USA).

    Expressing:

    Article Title: Granulocyte-macrophage colony-stimulating factor-transfected bone marrow stromal cells for the treatment of ischemic stroke ☆
    Article Snippet: Positive expression of factor VIII antibodies in vascular endothelial cells indirectly indicated proliferation of blood vessels. .. Reverse transcription-PCR detection of vascular endothelial growth factor mRNA To measure vascular endothelial growth factor mRNA expression, total RNA samples were extracted from the ischemic region at baseline (before MCAO; normal tissue), 24 hours after MCAO (before implantation), and 48 hours after MCAO in all groups using Trizol reagent (Invitrogen, Carlsbad, CA, USA). .. Vascular endothelial growth factor primers are as follows: forward: 5’-GTC CAA TTG AGA CCC TGG TG-3’; reverse: 5’-CTA TGT GCT GGC TTT GGT GA-3’.

    Incubation:

    Article Title: Survivin Modulates Squamous Cell Carcinoma-Derived Stem-Like Cell Proliferation, Viability and Tumor Formation in Vivo
    Article Snippet: Immunofluorescence Four micrometer skin sections from formalin fixed-paraffin tumors were rehydrated in PBS buffer and permeabilized by incubation for 10 min with 0.5% Triton X-100. .. Then, slides were incubated for 15 min with 0.5% bovine serum albumin and 5% goat serum, and for 60 min at 37 °C with the rabbit polyclonal anti-human Survivin antibody (1:50, Novus, Bloomington, MN, USA) or HIF1α (1:500, Novus, Bloomington, MN, USA), VEGF (1:50, Thermo Fisher Scientific, Waltham, MA, USA), CD51 (1:50, Abcam, Cambridge, UK). .. After four washes in PBS, samples were incubated for 60 min with the anti-rabbit secondary antibody, Alexa Fluor 546 (1:100, Thermo Fisher Scientific, Waltham, MA, USA).

    Article Title: C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways
    Article Snippet: .. For bFGF and VEGF treatments, CPCs were incubated with 50 ng/ml bFGF (Peprotech) or 20 ng/ml VEGF (Invitrogen) either alone or in combination with SCF as indicated. ..

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99
    Thermo Fisher cd34 ve cadherin vegf
    Expression of <t>CD34,</t> <t>VE-cadherin,</t> and <t>VEGF</t> protein under static culture and dynamic perfusion culture. (* p
    Cd34 Ve Cadherin Vegf, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd34 ve cadherin vegf/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cd34 ve cadherin vegf - by Bioz Stars, 2021-03
    99/100 stars
      Buy from Supplier

    97
    Thermo Fisher vegf
    ( a–f ) Role of <t>GLUT1</t> in <t>VEGF-induced</t> MC FN production. ( a ) Primary culture mouse MCs with the C57BL6 background were studied in culture with and without VEGF-A 165 peptide (2 ng/ml) for 48 h. VEGF-A 165 stimulated a two-fold increase in MC GLUT1
    Vegf, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vegf/product/Thermo Fisher
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    vegf - by Bioz Stars, 2021-03
    97/100 stars
      Buy from Supplier

    N/A
    VEGF Monoclonal Antibody for Western Blot ELISA
      Buy from Supplier

    Image Search Results


    Expression of CD34, VE-cadherin, and VEGF protein under static culture and dynamic perfusion culture. (* p

    Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

    Article Title: Dynamic Perfusion Culture of Human Outgrowth Endothelial Progenitor Cells on Demineralized Bone Matrix In Vitro

    doi: 10.12659/MSM.897884

    Figure Lengend Snippet: Expression of CD34, VE-cadherin, and VEGF protein under static culture and dynamic perfusion culture. (* p

    Article Snippet: Relative mRNA levels of CD34/VE-cadherin/VEGF were quantified by quantitative reverse transcriptase real-time PCR (QRT-PCR) using cDNA obtained from the reverse transcription reactions as template, with a StepOne instrument (Applied Biosystems) and SYBR-Green PCR Master Mix (Applied Biosystems).

    Techniques: Expressing

    The influence of dynamic perfusion culture on CD34/VE-cadherin/VEGF mRNA expression (* p

    Journal: Medical Science Monitor : International Medical Journal of Experimental and Clinical Research

    Article Title: Dynamic Perfusion Culture of Human Outgrowth Endothelial Progenitor Cells on Demineralized Bone Matrix In Vitro

    doi: 10.12659/MSM.897884

    Figure Lengend Snippet: The influence of dynamic perfusion culture on CD34/VE-cadherin/VEGF mRNA expression (* p

    Article Snippet: Relative mRNA levels of CD34/VE-cadherin/VEGF were quantified by quantitative reverse transcriptase real-time PCR (QRT-PCR) using cDNA obtained from the reverse transcription reactions as template, with a StepOne instrument (Applied Biosystems) and SYBR-Green PCR Master Mix (Applied Biosystems).

    Techniques: Expressing

    ( a–f ) Role of GLUT1 in VEGF-induced MC FN production. ( a ) Primary culture mouse MCs with the C57BL6 background were studied in culture with and without VEGF-A 165 peptide (2 ng/ml) for 48 h. VEGF-A 165 stimulated a two-fold increase in MC GLUT1

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF

    doi: 10.1038/labinvest.2009.95

    Figure Lengend Snippet: ( a–f ) Role of GLUT1 in VEGF-induced MC FN production. ( a ) Primary culture mouse MCs with the C57BL6 background were studied in culture with and without VEGF-A 165 peptide (2 ng/ml) for 48 h. VEGF-A 165 stimulated a two-fold increase in MC GLUT1

    Article Snippet: Immunohistochemical staining with various antibodies including GLUT1 (1:400, Alpha Diagnostic International, San Antonio, TX, USA), VEGF (1:200, Lab Vision, CA, USA), tenascin, phospho-PKCα (p-PKCα), and PKCβ1 (all 1:100, Santa Cruz Biotechnology, CA, USA), fibronectin (FN) and laminin (both 1:100, Sigma-Aldrich, St Louis, MO, USA), collagen IV (1:100, Santa Cruz Biotechnology, against α-1, α-3, and α-5 chains), CD2AP (1:100, Abcam, Cambridge, MA, USA), nephrin and podocin (both 1:100, kind gifts from Dr L Holzman, University of Michigan) was conducted using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with some modifications.

    Techniques:

    ( a–d ) Glomerular gene expression and glucose uptake rates in FvbROP Os/+ and FvbROP +/+ mice. ( a ) Western analyses of glomerular GLUT1, VEGF, PKCβ1, and PKCα in FvbROP +/+ and FvbROP Os/+ mice at 4 weeks of age ( n = 3–4

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF

    doi: 10.1038/labinvest.2009.95

    Figure Lengend Snippet: ( a–d ) Glomerular gene expression and glucose uptake rates in FvbROP Os/+ and FvbROP +/+ mice. ( a ) Western analyses of glomerular GLUT1, VEGF, PKCβ1, and PKCα in FvbROP +/+ and FvbROP Os/+ mice at 4 weeks of age ( n = 3–4

    Article Snippet: Immunohistochemical staining with various antibodies including GLUT1 (1:400, Alpha Diagnostic International, San Antonio, TX, USA), VEGF (1:200, Lab Vision, CA, USA), tenascin, phospho-PKCα (p-PKCα), and PKCβ1 (all 1:100, Santa Cruz Biotechnology, CA, USA), fibronectin (FN) and laminin (both 1:100, Sigma-Aldrich, St Louis, MO, USA), collagen IV (1:100, Santa Cruz Biotechnology, against α-1, α-3, and α-5 chains), CD2AP (1:100, Abcam, Cambridge, MA, USA), nephrin and podocin (both 1:100, kind gifts from Dr L Holzman, University of Michigan) was conducted using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with some modifications.

    Techniques: Expressing, Mouse Assay, Western Blot

    ( a–c ) Cyclic mechanical stretch induction of MC GLUT1 and VEGF expression. ( a ) GLUT1 protein levels were increased at 48 h of stretch, and remained elevated at 72 h (not shown). ( b ) VEGF protein expression was increased at 72h of stretch, but

    Journal: Laboratory investigation; a journal of technical methods and pathology

    Article Title: Nephron-deficient Fvb mice develop rapidly progressive renal failure and heavy albuminuria involving excess glomerular GLUT1 and VEGF

    doi: 10.1038/labinvest.2009.95

    Figure Lengend Snippet: ( a–c ) Cyclic mechanical stretch induction of MC GLUT1 and VEGF expression. ( a ) GLUT1 protein levels were increased at 48 h of stretch, and remained elevated at 72 h (not shown). ( b ) VEGF protein expression was increased at 72h of stretch, but

    Article Snippet: Immunohistochemical staining with various antibodies including GLUT1 (1:400, Alpha Diagnostic International, San Antonio, TX, USA), VEGF (1:200, Lab Vision, CA, USA), tenascin, phospho-PKCα (p-PKCα), and PKCβ1 (all 1:100, Santa Cruz Biotechnology, CA, USA), fibronectin (FN) and laminin (both 1:100, Sigma-Aldrich, St Louis, MO, USA), collagen IV (1:100, Santa Cruz Biotechnology, against α-1, α-3, and α-5 chains), CD2AP (1:100, Abcam, Cambridge, MA, USA), nephrin and podocin (both 1:100, kind gifts from Dr L Holzman, University of Michigan) was conducted using a Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA, USA) with some modifications.

    Techniques: Expressing

    c-kit activation promotes growth of human c-kit+ CPCs under serum starvation. A, Activation of c-kit by SCF in human c-kit+ CPCs. CPCs were either treated with SCF (100 ng/ml) alone for 10 minutes or co-treated with imatinib. Cell lysate was analyzed by Western blot for the indicated proteins. p-c-kit, phosphorylated (i.e., activated) c-kit. B, Effect of SCF on cell growth. CPCs were serum starved for 24 hr and treated with SCF. The number of cells remaining was counted at the indicated time points. C, Dose-response relationship between SCF and CPC growth. CPCs were serum starved for 24 hr followed by treatment with varying concentrations of SCF, and the number of cells remaining after 3 days was determined. D, Representative DAPI nuclear staining images of SCF-treated CPCs described in panel C. E, Comparison of SCF with bFGF and VEGF in promoting growth of CPCs. CPCs were serum starved for 24 hr and treated with SCF, bFGF, or VEGF either individually or in combination, and the number of cells were counted on days 5 and 9 of treatment. F, Human c-kit+ CPCs were transduced with lentivirus expressing mCherry (control) or c-kit. Cell lysates were obtained at 4 days post-viral transduction and immunoblotted for c-kit and α-tubulin (loading control). G, mCherry or c-kit-expressing CPCs were serum starved for 24 hr and cultured for 3 days in the presence (+) or absence (-) of SCF and/or imatinib as indicated. Cell viability was assessed using PrestoBlue TM as described. Values were normalized to the DMSO (vehicle) control. Values are presented as mean ± SEM. *, p

    Journal: PLoS ONE

    Article Title: C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways

    doi: 10.1371/journal.pone.0140798

    Figure Lengend Snippet: c-kit activation promotes growth of human c-kit+ CPCs under serum starvation. A, Activation of c-kit by SCF in human c-kit+ CPCs. CPCs were either treated with SCF (100 ng/ml) alone for 10 minutes or co-treated with imatinib. Cell lysate was analyzed by Western blot for the indicated proteins. p-c-kit, phosphorylated (i.e., activated) c-kit. B, Effect of SCF on cell growth. CPCs were serum starved for 24 hr and treated with SCF. The number of cells remaining was counted at the indicated time points. C, Dose-response relationship between SCF and CPC growth. CPCs were serum starved for 24 hr followed by treatment with varying concentrations of SCF, and the number of cells remaining after 3 days was determined. D, Representative DAPI nuclear staining images of SCF-treated CPCs described in panel C. E, Comparison of SCF with bFGF and VEGF in promoting growth of CPCs. CPCs were serum starved for 24 hr and treated with SCF, bFGF, or VEGF either individually or in combination, and the number of cells were counted on days 5 and 9 of treatment. F, Human c-kit+ CPCs were transduced with lentivirus expressing mCherry (control) or c-kit. Cell lysates were obtained at 4 days post-viral transduction and immunoblotted for c-kit and α-tubulin (loading control). G, mCherry or c-kit-expressing CPCs were serum starved for 24 hr and cultured for 3 days in the presence (+) or absence (-) of SCF and/or imatinib as indicated. Cell viability was assessed using PrestoBlue TM as described. Values were normalized to the DMSO (vehicle) control. Values are presented as mean ± SEM. *, p

    Article Snippet: For bFGF and VEGF treatments, CPCs were incubated with 50 ng/ml bFGF (Peprotech) or 20 ng/ml VEGF (Invitrogen) either alone or in combination with SCF as indicated.

    Techniques: Activation Assay, Western Blot, Staining, Transduction, Expressing, Cell Culture

    c-kit activation promotes migration of CPCs. Boyden chamber assay. Human c-kit+ CPCs were plated in the upper chamber, and the indicated growth factors were used as a chemoattractant in the lower chamber. After 24 hr, the migrated cells were fixed, stained with propidium iodide, and counted. A, Comparison of the pro-migratory effect of SCF and VEGF. B, Representative images showing the cells that migrated towards the indicated growth factors. C, CPCs transduced with lentivirus expressing mCherry (control) or c-kit were compared for their chemotaxis towards SCF in the presence (+) or absence (-) of 0.5 mM imatinib. Values presented are mean ± SEM. *, p

    Journal: PLoS ONE

    Article Title: C-Kit Promotes Growth and Migration of Human Cardiac Progenitor Cells via the PI3K-AKT and MEK-ERK Pathways

    doi: 10.1371/journal.pone.0140798

    Figure Lengend Snippet: c-kit activation promotes migration of CPCs. Boyden chamber assay. Human c-kit+ CPCs were plated in the upper chamber, and the indicated growth factors were used as a chemoattractant in the lower chamber. After 24 hr, the migrated cells were fixed, stained with propidium iodide, and counted. A, Comparison of the pro-migratory effect of SCF and VEGF. B, Representative images showing the cells that migrated towards the indicated growth factors. C, CPCs transduced with lentivirus expressing mCherry (control) or c-kit were compared for their chemotaxis towards SCF in the presence (+) or absence (-) of 0.5 mM imatinib. Values presented are mean ± SEM. *, p

    Article Snippet: For bFGF and VEGF treatments, CPCs were incubated with 50 ng/ml bFGF (Peprotech) or 20 ng/ml VEGF (Invitrogen) either alone or in combination with SCF as indicated.

    Techniques: Activation Assay, Migration, Boyden Chamber Assay, Staining, Transduction, Expressing, Chemotaxis Assay

    NCTD inhibits the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins/mRNAs of the in-situ colonic xenografts in vivo. a Western-blotting: the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins in NCTD, Sorafenib, or NCTD + Sorafenib group was significantly downregulated as compared to control group (* P

    Journal: BMC Cancer

    Article Title: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

    doi: 10.1186/s12885-015-1521-5

    Figure Lengend Snippet: NCTD inhibits the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins/mRNAs of the in-situ colonic xenografts in vivo. a Western-blotting: the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins in NCTD, Sorafenib, or NCTD + Sorafenib group was significantly downregulated as compared to control group (* P

    Article Snippet: For S-P staining, slides were treated according to the kit brochure (Jinmei Biotechnology Co., Ltd., Shanghai), added in order with primary antibody [rabbit anti-human monoclonal antibody VEGF-A (Santa Gruz), VEGF-C (Invitrogen), VEGF-D (Abcam, USA), VEGFR-2 (Cell Signaling, USA), VEGFR-3 (Cell Signaling), biotinylated anti-rabbit secondary, HRP logo Streptavidin and DAB solution, respectively.

    Techniques: Expressing, In Situ, In Vivo, Western Blot

    The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins/mRNAs of HCACCs and the co-culture system and the effect of NCTD on expression of these proteins/ mRNAs by western blotting ( a and b ) and fluorescent quantitative RT-PCR ( c and d ) in vitro . a and b Protein expression by western blotting: the expression of VEGF-C, VEGF-D and VEGFR-3 proteins of the co-culture system was higher than those of alone HCACC culture (* P = 0.001), but there was no difference on VEGF-A and VEGFR-2 expression between alone HCACC culture and the co-culture system. After treatment with NCTD, mF4-31C1 or NCTD + mF4-31C1, the expression of VEGF-C, VEGF-D and VEGFR-3 proteins of the co-culture system was downregulated significantly as compared to control group (all * P

    Journal: BMC Cancer

    Article Title: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

    doi: 10.1186/s12885-015-1521-5

    Figure Lengend Snippet: The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins/mRNAs of HCACCs and the co-culture system and the effect of NCTD on expression of these proteins/ mRNAs by western blotting ( a and b ) and fluorescent quantitative RT-PCR ( c and d ) in vitro . a and b Protein expression by western blotting: the expression of VEGF-C, VEGF-D and VEGFR-3 proteins of the co-culture system was higher than those of alone HCACC culture (* P = 0.001), but there was no difference on VEGF-A and VEGFR-2 expression between alone HCACC culture and the co-culture system. After treatment with NCTD, mF4-31C1 or NCTD + mF4-31C1, the expression of VEGF-C, VEGF-D and VEGFR-3 proteins of the co-culture system was downregulated significantly as compared to control group (all * P

    Article Snippet: For S-P staining, slides were treated according to the kit brochure (Jinmei Biotechnology Co., Ltd., Shanghai), added in order with primary antibody [rabbit anti-human monoclonal antibody VEGF-A (Santa Gruz), VEGF-C (Invitrogen), VEGF-D (Abcam, USA), VEGFR-2 (Cell Signaling, USA), VEGFR-3 (Cell Signaling), biotinylated anti-rabbit secondary, HRP logo Streptavidin and DAB solution, respectively.

    Techniques: Expressing, Co-Culture Assay, Western Blot, Quantitative RT-PCR, In Vitro

    The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 protein products of HCACCs and the co-culture system of each group and the effect of NCTD on expression of these protein products in vitro (S-P staining, magnification × 200). a The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 protein products of HCACCs and the co-culture system of each group. The expression of VEGF-C, VEGF-D and VEGFR-3 protein products (brown staining in cytoplasm) of the co-culture system was higher than those of alone HCACC culture (* P = 0.001); but there is no difference on the expression of VEGF-A and VEGFR-2 protein products between alone HCACC culture and the co-culture system. b The inhibitory effect of NCTD on expression of these protein products of the co-culture system. The expression of VEGF-C, VEGF-D and VEGFR-3 protein products in NCTD, mF4-31C1 or NCTD + mF4-31C1 group was downregulated significantly as compared to control group (* P

    Journal: BMC Cancer

    Article Title: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

    doi: 10.1186/s12885-015-1521-5

    Figure Lengend Snippet: The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 protein products of HCACCs and the co-culture system of each group and the effect of NCTD on expression of these protein products in vitro (S-P staining, magnification × 200). a The expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 protein products of HCACCs and the co-culture system of each group. The expression of VEGF-C, VEGF-D and VEGFR-3 protein products (brown staining in cytoplasm) of the co-culture system was higher than those of alone HCACC culture (* P = 0.001); but there is no difference on the expression of VEGF-A and VEGFR-2 protein products between alone HCACC culture and the co-culture system. b The inhibitory effect of NCTD on expression of these protein products of the co-culture system. The expression of VEGF-C, VEGF-D and VEGFR-3 protein products in NCTD, mF4-31C1 or NCTD + mF4-31C1 group was downregulated significantly as compared to control group (* P

    Article Snippet: For S-P staining, slides were treated according to the kit brochure (Jinmei Biotechnology Co., Ltd., Shanghai), added in order with primary antibody [rabbit anti-human monoclonal antibody VEGF-A (Santa Gruz), VEGF-C (Invitrogen), VEGF-D (Abcam, USA), VEGFR-2 (Cell Signaling, USA), VEGFR-3 (Cell Signaling), biotinylated anti-rabbit secondary, HRP logo Streptavidin and DAB solution, respectively.

    Techniques: Expressing, Co-Culture Assay, In Vitro, Staining